Pasadena, Ca., USA - November 4, 2009, Pasadena, Ca., USA - Arrowhead Research Corporation, a nanotechnology company announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui and Bruce D. Given to its Board of Directors.
Article continues below
Dr. Given is a healthcare products consultant and is the Principal of Bruce Given Consulting. Prior to the establishment of his consulting practice, Dr. Given was President and Chief Executive Officer of Encysive Pharmaceuticals Inc., which was subsequently acquired by Pfizer. Prior to joining Encysive, he was with Johnson & Johnson for nine years, serving in several capacities including as President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica, Inc.
He has held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago. Dr. Given currently serves on the Board of Directors for ICON Plc, BioHouston, and for the Texas Life Science Center. He is a member of the Technology Review Committee of MD Anderson Medical Center, and is past Chairman of the Rider University Scientific Advisory Board.
Dr. Given is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Given's honors include the Franklin McLean Research Award from the University of Chicago, election to Alpha Omega Alpha and the Provost Award from Colorado State University.
Providing industry leadership in the biomedical and technology fields, Dr. Analoui is actively involved in investment, management, and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. Currently, he serves as head of Healthcare and Life Science at The Livingston Group, a specialty investment firm located in New York, NY and Senior Vice President of Business Development at Charlesson Pharmaceuticals.
Previously he was the Senior Director at Pfizer Inc. Global Research and Development, where he led the platform technology mission for the clinical development and commercial division in areas including the medical imaging, diagnostics computational medicine, knowledge management and non-invasive measurement monitoring. He was also President and CEO of Therametric Technology Inc.
Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research at Indiana University where he still serves as an adjunct faculty member, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He has also served on various scientific, regulatory, and business advisory committees and boards. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. ■